USA flag logo/image

An Official Website of the United States Government

Valens: A Mass Spectrometry-Based Antibody Sequencing Tool by Digital Proteomics

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43GM103346
Solicitation Year:
2012
Solicitation Topic Code:
NIGMS
Solicitation Number:
PA11-215
Small Business Information
DIGITAL PROTEOMICS, LLC
4519 49th Street SAN DIEGO, CA 92115-3238
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Valens: A Mass Spectrometry-Based Antibody Sequencing Tool by Digital Proteomics
Agency: HHS
Contract: 1R43GM103346-01
Award Amount: $480,109.00
 

Abstract:

DESCRIPTION (provided by applicant): Monoclonal antibodies exhibit high specificity for target molecules and for that reason have been successfully utilized as therapeutic and diagnostic agents. The sequence of amino acids comprising the primary structureof an antibody is largely responsible for its binding preference and efficacy. Therefore, antibody sequencing is a central requirement for the development of novel antibody therapies. We propose a method of performing antibody sequencing directly from theprotein sequence, without requiring the source cell, which makes it practical for many lab and clinical settings. In addition, our proposed computational method is fully automated, and will increase throughput by dramatically reducing the time required forsequencing from weeks to hours. We plan to implement our method in both a stand-alone tool that may be run on a single desktop computer, or make use of the vast resources available in cloud computing. We will also provide an in-house sequencing servicefor users without access to the mass spectrometry equipment or computing resources. PUBLIC HEALTH RELEVANCE: Characterizing the sequence of an antibody is a prerequisite for the development of antibody based therapies and diagnostic methods, which represent a growing segment of the drug market. We propose a novel computational method of antibody sequencing based on mass spectrometry, which will dramatically increase the rate of antibody characterization, and reduce the time from development in thelab to treatment in the clinic.

Principal Investigator:

Natalie Castellana
703-727-0820
ncastell@gmail.com

Business Contact:

Natalie Castellana
703-727-0820
ncastell@gmail.com
Small Business Information at Submission:

DIGITAL PROTEOMICS, LLC
4519 49th Street SAN DIEGO, CA 92115-3238

EIN/Tax ID: 127147679
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No